Literature DB >> 26988379

Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST.

Laurence D Sterns1, Mathias Meine2, Takashi Kurita3, Albert Meijer4, Angelo Auricchio5, Kenji Ando6, Charles T Leng7, Ken Okumura8, John L Sapp9, Mark L Brown10, Daniel R Lexcen10, Bart Gerritse11, Edward J Schloss12.   

Abstract

BACKGROUND: Prolonged ventricular fibrillation (VF) detection has been shown to reduce implantable cardioverter-defibrillator (ICD) therapies and improve prognosis in primary prevention ICD patients. Data in secondary prevention patients are limited.
OBJECTIVE: The PainFree SST secondary prevention study is the largest trial of secondary prevention patients randomized between standard and prolonged detection to assess the safety of this strategy in these patients.
METHODS: A total of 705 secondary prevention patients implanted with an ICD in the PainFree SST trial were enrolled in this substudy; 353 patients were randomized to VF detection of 18/24 intervals and 352 patients to 30/40. All other VF parameters were standardized by protocol.
RESULTS: The 1-year arrhythmic syncope-free rates in the standard and prolonged groups were 97.7% vs 96.9%, respectively, (P = .0034 for noninferiority). Freedom from all-cause syncope was 96% in both arms (P = .0013 for noninferiority). There was no difference in the time to first appropriate or inappropriate VF therapy. However, the rates of treated VF episodes were lower in the prolonged arm (1.48 per patient per year vs 0.44 per patient per year, P = .0001). A trend toward lower mortality in the prolonged group was not statistically different (5.6% 1 year, 12% 2 years vs 3.8% 1 year, 7.7% 2 years, adjusted hazard ratio = 0.60, P = .061).
CONCLUSION: This large prospective randomized study shows that prolonged detection can safely be programmed in secondary prevention ICD patients with new or existing devices. This programming strategy decreases the rate of treated events and is not associated with an increased risk of syncope or mortality.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Implantable defibrillator; Inappropriate shocks; Shock reduction algorithm; Ventricular fibrillation; Ventricular tachycardia

Mesh:

Year:  2016        PMID: 26988379     DOI: 10.1016/j.hrthm.2016.03.022

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  5 in total

Review 1.  Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.

Authors:  Amir AbdelWahab; John Sapp
Journal:  Curr Cardiol Rep       Date:  2017-09-13       Impact factor: 2.931

2.  Electrical storm: mechanistic and therapeutic considerations to avoid death in the survivors.

Authors:  Yukiomi Tsuji; Dobromir Dobrev
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 3.005

3.  The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?

Authors:  Giovanni Luca Botto; Giovanni B Forleo; Alessandro Capucci; Francesco Solimene; Antonello Vado; Giovanni Bertero; Pietro Palmisano; Ennio Pisanò; Antonio Rapacciuolo; Tommaso Infusino; Alessandro Vicentini; Miguel Viscusi; Paola Ferrari; Antonello Talarico; Giovanni Russo; Giuseppe Boriani; Luigi Padeletti; Mariolina Lovecchio; Sergio Valsecchi; Antonio D'Onofrio
Journal:  Europace       Date:  2017-11-01       Impact factor: 5.214

4.  Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Authors:  Mehmet K Aktas; Amanda L Bennett; Arwa Younis; Valentina Kutyifa; Bronislava Polonsky; Scott McNitt; Wojciech Zareba; Spencer Rosero; Ilan Goldenberg
Journal:  Heart Rhythm O2       Date:  2020-05-11

5.  The Effect of Shock Burden on Heart Failure and Mortality.

Authors:  Ciorsti J MacIntyre; John L Sapp; Amir Abdelwahab; Mousa Al-Harbi; Steve Doucette; Chris Gray; Martin J Gardner; Ratika Parkash
Journal:  CJC Open       Date:  2019-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.